Trastuzumab in inflammatory breast cancer
- 18 August 2008
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 19 (10) , 1815-1817
- https://doi.org/10.1093/annonc/mdn555
Abstract
Inflammatory breast cancer (IBC) is associated with poor survival, specifically hormone receptor-negative subtype [1].Keywords
This publication has 5 references indexed in Scilit:
- Trends for Inflammatory Breast Cancer: Is Survival Improving?The Oncologist, 2007
- Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative PhenotypeClinical Cancer Research, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003